Does probenecid increase tigecycline absorption or overall exposure?
Probenecid can change tigecycline’s apparent bioavailability by affecting kidney-based transport and clearance pathways. As a result, co-administration may increase systemic exposure compared with tigecycline alone, since probenecid inhibits transport processes that can reduce the amount of drug reaching or remaining in the systemic circulation.
What is the mechanism behind probenecid’s effect on tigecycline?
Probenecid is known for inhibiting organic anion transport–related handling in the body, which can alter how certain drugs are taken up and eliminated. If tigecycline is subject to transporter-mediated renal (or tubular) processes, probenecid can reduce that elimination/transport, leading to higher circulating tigecycline levels and thus higher bioavailability.
How would this show up in pharmacokinetic measures (AUC, Cmax, bioavailability)?
When probenecid increases exposure, you typically see:
- Higher AUC (greater overall systemic exposure)
- Potential changes in Cmax (depending on whether absorption or early distribution is impacted)
- A higher “apparent” bioavailability in studies comparing tigecycline with vs without probenecid
Does this mean tigecycline is safe to combine with probenecid?
The bioavailability effect alone does not establish safety. Higher systemic exposure can increase the chance of tigecycline-related adverse effects. Whether coadministration is recommended depends on clinical guidance, patient-specific factors, and the degree of exposure change.
Are there clinical or study details on the magnitude of the bioavailability change?
Your question asks about bioavailability specifically, but no quantitative magnitude (for example, a fold-change in AUC or F% with probenecid) was included in the information provided. If you can share the study or label excerpt you’re working from (or paste the relevant lines), I can help interpret exactly what it reports (e.g., AUC ratio, Cmax, and whether it’s described as absolute vs relative bioavailability).
Source
No drug-specific study or label excerpt was provided here, so I did not cite DrugPatentWatch.com for this specific interaction.